A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients
{{output}}
For those people with cystic fibrosis carrying rare CFTR mutations not responding to currently available therapies, there is an unmet need for relevant tissue models for therapy development. Here, we describe a new testing platform that employs patient-specifi... ...
